Additional biomarkers (e.g., CTLA-4, PD-L1 combined positive score, tumor mutational burden, and measures of tumor-infiltrating lymphocytes) are increasingly used to guide ICI eligibility or to stratify risk. This evidence concerns the gene CD274 and neoplasm.